Vaccine Presentation in the USA: Economics of Prefilled Syringes versus Multidose Vials for Influenza Vaccination

Claudia C Pereira; David Bishai


Expert Rev Vaccines. 2010;9(11):1343-1349. 

In This Article


This work shows that the costs of vaccine administration using PFSs are lower than using MDVs. These costs primarily reflect the longer average time required to prepare a dose of vaccine from a MDV.

Given the current US scenario and system of reimbursement from health plans, the small price gap between MDVs and PFSs and storage requirements are likely to be the main reasons that practices have not yet completely switched to PFSs in the case of influenza vaccines. Furthermore, from the perspective of the clinics, those that receive most of their supplies through the Vaccines for Children Program would benefit the most from the time and convenience of PFSs compared with MDVs, as they are not incurring the expense of the vaccines. Mass vaccination clinics would need to weigh the relative convenience of PFSs in relation to MDVs, versus the full cost of both.

There are strong indications that the growth of PFS penetration into the market for vaccines will continue as American consumers and providers become more familiar with the advantages of these products.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: